Petrovax has received a patent for the original medicine product Longidaza®, which is valid in South Korea protecting.
During the COVID-19 pandemic, the drug product helps to cope with post-COVID consequences accompanied by impaired lung function. Shortness of breath is one of the most common symptoms that can persist for a long time after infection and represents a manifestation of inflammatory changes in the lungs of patients who had COVID-19.
In 2020–2021, Petrovax conducted an additional study to assess the efficacy and safety of Longidaza®. It showed good results in the treatment of patients who had COVID-19. Those patients made good progress and recovered faster from the disease.
In 2021, sales of the drug product in Russia and worldwide exceeded 1.7 million packs. Out of these numbers, the share of export supplies of the drug product was 9%.
In addition to Russia, today Longidase ® is registered in six countries: Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan, and Ukraine. Registration in Belarus is expected. This year, the company plans to submit applications in Georgia, Azerbaijan, and Mongolia.
Previously, Pharmpro.net reported that Longidaza® received a patent in India. Thus, Longidaza® entered the markets of the BRICS countries (an interstate group comprising of the Federative Republic of Brazil, the Russian Federation, the Republic of India, the People’s Republic of China and the Republic of South Africa, established in June 2006 on the initiative of the Russian side).
It is planned that the Republic of Korea will become a new market on the export medicine’s map.